Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset
Enrique Zudaire(Centro de Investigación del Cáncer), Sundar Jagannath(Mount Sinai Hospital), Deepu Madduri(Johnson & Johnson (United States)), Syed Rizvi(Merck (Japan)), Tonia Nesheiwat, Jesús G. Berdeja(Tennessee Oncology), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Andrzej Jakubowiak(University of Chicago Medical Center), Ian McCaffery(Amgen (United States)), Jordan M. Schecter(Centro de Investigación del Cáncer), Indrajeet Singh(Janssen (United States)), Alicia J. Allred(Queen's University Belfast), Dong Geng, Saad Z. Usmani(Memorial Sloan Kettering Cancer Center)
Cited by 29
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k